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Background: The purpose of this study was to evaluate the combined effect of different pre-hemodialysis (HD)
serum sodium (S[Na]) and potassium (S[K]) concentrations on the long-term prognosis of HD patients.
Methods: A cohort of 424 maintenance HD patients (age: 58 ± 13 years, male: 47%, diabetes: 39%) from a single
center were divided into four groups based on both medians of S[Na] (138.4 mmol/L) and S[K] (4.4 mmol/L): Group
1: lower S[Na] & lower S[K]: n = 92; Group 2: lower S[Na] & higher S[K]: n =113; Group 3: higher S[Na] & lower S[K]:
n =123; Group 4: higher S[Na] & higher S[K]: n =96. The median observation period was 21 months.
Result: By multivariate logistic regression analysis, Group 1 was characterized by hypoalbuminemia (OR = 0.37, 95%
CI = 0.20-0.67), and lower normalized protein catabolism rate (nPCR) (OR = 0.37, 95% CI = 0.16-0.83). In contrast, Group 4
was characterized by higher nPCR (OR = 2.26, 95% CI = 1.05-4.86) and albumin level (OR = 2.26, 95% CI = 1.17-4.39). As
compared to the reference (group 1), the HR for long-term mortality was significantly lower in Groups 3 (HR = 0.54,
95% CI = 0.34- 0.86) and 4 (HR = 0.49, 95% CI = 0.28-0.84). By multivariate Cox proportional analysis, Group 1 was
an independent factor (HR = 1.74, 95% CI = 1.18-2.58) associated with long-term mortality.
Conclusion: HD patients combined with lower S[K] and lower S[Na] were characterized by hypoalbuminemia,
lower nPCR and a high prevalence of co-morbidity. They were associated with long-term mortality risk. On the
other hand, those patients with higher levels of S[Na] and S[K] tended to have better clinical outcomes.
Keywords: Hypokalemia, Hyponatremia, End-stage renal disease, Malnutrition, Inflammation, Chronic
kidney diseaseBackground
Hyponatremia has been reported to be associated with
high mortality rates under various conditions [1-4]. Hos-
pitalized patients with hyponatremia had an increased
death risk during their hospital stay, and across 1 to
5 years’ follow-up [5]. Patients with hyponatremia were
found to often be associated with more severe diseases
and a high percentage of co-morbidities [6]. It has been
suggested that the nature of underlying illness rather
than the severity of hyponatremia better explains its
associated mortality [7]. Sodium balance in hemodialysis
(HD) patients is primarily dependent on two factors:* Correspondence: alfonjch@seed.net.tw
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reproduction in any medium, provided the ordietary salt intake and sodium removal during dialysis.
Salt intake during the inter-dialytic period is dependent
on patient behavior and is a strong driver of volume
overload, whereas in current HD practice, most sodium is
removed by convection [8]. Some study has documented
the impact of serum sodium concentration (S[Na]) on
the long-term prognosis for HD patients [9].
Pre-HD hyperkalemia (hyperK) was associated with higher
all-cause and cardiovascular mortality in HD patients [10].
The association of higher dialysate potassium concentration
with increased mortality in pre-HD hyperK patients has
also been observed [11]. Hypokalemia (hypoK), in contrast,
is a less common concern in chronic kidney disease (CKD)
patients, being a poor prognostic factor for CKD patients’
long-term survival [12,13]. In heart failure patients with
CKD, a serum potassium level (S[K]) lower than 4 mmol/LLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hospitalization [14].
No study has so far addressed the impact of the combined
effect of pre-HD S[Na] and S[K] on long term-survival
of chronic HD patients. These two markers are easily
accessible and routinely monitored in clinical practice.
Moreover, unexplained hypokalemia may indicate protein-
energy malnutrition in dialysis patients [10], while predia-
lysis S[Na] may be a marker of free water intake [9].
Therefore, in this study, by taking into account both of
these electrolytes, we aimed to analyze the clinical features
of HD patients stratified by different levels of S[Na]
and S[K] and also to compare the long-term prognostic
effect of each group of patients.
Methods
This study was a cohort observational study of pro-
spectively collected data based on the database that was
constructed for outcome assurance from January 2004
to July 2008 at Chi Mei Medical Center. Excluded from
the study were patients receiving HD for fewer than
6 months (n = 18), those suspected of having acute renal
failure (n = 6), and those with prescribed long-term
diuretics usage and potassium-reducing agents (n = 2).
A total of 424 end-stage renal disease (ESRD) patients
undergoing maintenance HD thrice a week, 4 hours
per session, at our unit in January 2004 were enrolled
in this study. Based on the median pre-dialysis S[Na]
as assessed on the last mid-week dialysis session of
January 2004, the patients were categorized as lower
Na (S[Na] ≦ 138.4 mmol/L, n = 205) and higher Na groups
(S[Na] > 138.4 mmol/L, n = 219). With median S[K]
(4.4 mmol/L) as a cut-off, the patients with lower S[Na]
were further subdivided into two groups: Group 1 (n = 92):
patients with S[K] ≦ 4.4 mmol/L; Group 2 (n = 113): pa-
tients with S[K] > 4.4 mmol/L. Using the same criteria,
the patients with higher S[Na] were also sub-divided
into Group 3 (lower S[K], n = 123) and Group 4 (higher
S[K], n = 96). The hollow-fiber dialyzers applied to all
patients included the FB210G (Nissho Corporation,
Osaka, Japan), B3-2.0 (Toray Industries, Inc, Tokyo,
Japan), Hemoflow F10 HPS (Fresenius Medical Care
AG, Bad, Homburn, Germany), and PSN-210 (Baxter
Healthcare Corporation, McGaw Park, IL, USA). The
formula of the dialysate bath used at the initiation of
the study was sodium: 140.0 mmol/L, calcium: 3.0 mmol/L,
potassium: 1.0 mmol/L, magnesium: 1.0 mmol/L, chloride:
104.5 mmol/L, acetate: 4.0 mmol/L, dextrose: 200 mg/dl,
and bicarbonate: 35 mmol/L (Renasol® SB-1080, Renal
System, Minneapolis, MN, USA). For cost reasons,
from July 2004 to the end of the study we used another
dialysate (Hemodialysis Concentrate A-35 & BP-11, Chi
Sheng Chemical Corporation, Hsinchu, Taiwan). The
formula of the second dialysate was sodium: 139.0 mmol/L,calcium: 3.0 mmol/L, potassium: 2.0 mmol/L, magnesium:
1.0 mmol/L, chloride: 106.5 mmol/L, acetate: 4.0 mmol/L,
dextrose: 200 mg/dL, and bicarbonate: 39 mmol/L. No
changes of potassium concentration in the dialysate bath
or dialysate sodium remodeling process were prescribed
though the study period.
Blood samples were taken in the last mid-week of
January 2004 at the beginning of the study and every
six months thereafter until September 2008. Pre-HD
biochemical analysis including serum albumin by means
of bromocresol purple, potassium, urea nitrogen (BUN),
creatinine, uric acid and phosphate concentrations were
measured by the Hitachi 7601–110 Automatic Analyzer
(Tokyo, Japan). Serum sodium level was corrected by
1.6 mmol/L for every 100 mg/dL increase in glucose
level because water transfers from the intracellular to
extracellular compartment [15]. Hematocrit was measured
by the Beckman Coulter LH755-A (Fullerton, CA, USA).
High sensitive C-reactive protein (hs-CRP) (CardioPhase®
Siemens Healthcare Diagnostics Products, GmbH, Germany)
and prealbumin (immunochemical method, Dade Behring
Marburg GmbH, Germany) were also checked. The data
of those patients who were transferred to other centers or
who died during the study were omitted on a monthly
basis, as seen in Figure 1. We also evaluated the KT/V
urea (Gotch formula) and normalized protein catabolism
(nPCR) for all patients at the beginning of study to compare
the difference in dialysis dosage and protein intake between
each group [16].
The co-morbidity factors were accessed according to
the past history recorded in the medical charts at the
beginning of study. Coronary artery disease was defined
as positive in the case of any of the following: evidence
of abnormalities at coronary angiography, Tc99m-thallium
scan, events of acute myocardial infarction, regional hypo-
or akinesia of myocardium proved by echocardiography,
and regular follow-up at the cardiovascular section for
ischemic heart disease. Congestive heart failure was
defined according to the criteria of New York Heart
Association classification. Peripheral vascular disease
was defined as chronic ulcers of the lower extremities
for more than one month, and/or a history of amputation
for vascular insufficiency. Stroke was defined as clinical
and/or image evidence of ischemic brain syndrome or
non-traumatic intracranial hemorrhage. Neoplasm was
defined by the positive image and/or pathology evidence
of malignancy including hematological malignancy. Chronic
lung disease was defined as chronic obstructive pulmonary
disease under long-term treatment with prednisolone
and/or bronchodilators at the chest medicine section.
Hepatitis and liver cirrhosis were evidenced by abnormal
liver function for more than half a year and a positive
result for chronic changes in abdominal sonography.
The research was approved by the Ethics Committee of
Figure 1 Long-term serum sodium, potassium and albumin concentrations. Those patients with lower serum sodium (S[Na], Groups 1 and
2) and potassium concentrations (S[K], Groups 1 and 3) at baseline had persistently lower S[Na] and S[K] (1A and 1C). They also had consistently
lower serum albumin concentrations (1B and 1D). All the deceased patients were excluded serially. (a: p < 0.001; b: p < 0.05; compared to lower S
[Na], or lower S[K], unpaired Student t tests).
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with the guiding principles for human experimentation of
the Helsinki Declaration.
Statistical analysis
Appropriate χ2 and ANOVA with post hoc Bonferroni
tests were used for comparisons between categorical and
continuous variables, respectively, between the groups,
as shown in Table 1 and Figure 1. The hs-CRP compari-
sons among the 4 groups were undertaken with the
Kruskal-Wallis one-way analysis of variance. For the
evaluation of clinical features of the patients of Group 1
and Group 4, risk factors including nPCR, albumin, dia-
betes mellitus, gender, age at initiation of study, and HD
vintage were analyzed by stepwise forward multivariate
logistic regression tests (Table 2). Actuarial survival rates
of the four groups categorized by different pre-HD S
[Na] and S[K] were determined by the Kaplan-Meier
methods, and log rank tests were employed to compare
the different survival curves between groups. Cox pro-
portional hazard methods were also performed to
analyze the risk factors associated with long-term mor-
tality (Table 3). With the exception of hs-CRP (median,
inter-quartile ranges), all the other data are expressed as
mean ± standard deviation. A p value of less than 0.05
was considered to be significant. Computations were
performed with the SPSS 17.0 package for Windows
(SPSS, Chicago, IL, USA).Results
Basic demographic characteristics of four groups
of patients
Although the differences between Groups 1 and 3 were
not statistically significant, Group 1 had lower nPCR,
Karnofsky score, and percentage of non-comorbidity
than Groups 2 and 4 (Table 1). Serum levels of albu-
min, phosphate, uric acid, and pre-HD BUN were also
significantly lower in Group 1compared to Groups 2
and 4. Among the 4 groups, Group 1 had the highest
hs-CRP and lowest pre-albumin and Cr levels. On the
other hand, Group 4 had statistically higher nPCR, pre-
albumin, albumin, phosphate, BUN, and uric acid
levels than those of Group 3. There were no significant
differences in gender ratio, age at the initiation of
study, HD vintage, Kt/V, ultrafiltration rate, mean
blood pressure, percentage for DM, use of ACEI and/
or ARB and hematocrit levels among the four groups
of patients.
In a comparison of each electrolyte, the lower S[K]
group (Groups 1 and 3) had significantly higher hs-
CRP level (3.85 mg/dL, 1.13-11.7 mg/dL vs. 2.65 mg/dL,
0.78-6.64 mg/dL, p = 0.015), lower nPCR (1.18 ± 0.33 vs.
1.32 ± 0.31 g/kg/day, p < 0.001) and serum albumin
concentration (3.8 ± 0.5 vs. 4.0 ± 0.4 g/dL, p < 0.001)
compared to the their high group counterparts. On
the other hand, higher hs-CRP level (4.32 mg/L, 1.02-
11.8 mg/L vs. 2.31 mg/dL, 0.92-5.81 mg/L, p = 0.002),
Table 1 Basic demographic characteristic of the four groups of patients
Group1 Group 2 Group 3 Group 4
n = 92 n = 113 n = 123 n = 96
Demographic factors
Diabetes mellitus, % 43 44 37 30
Male, % 40 43 50 53
Age at study, years 60 ± 13 57 ± 12 58 ± 13 57 ± 13
HD vintage, months 49.8 ± 44.6 48.9 ± 44.2 55.0 ± 45.6 48.8 ± 38.7
Ultrafiltration, L/session 2.6 ± 0.8 2.9 ± 0.7 2.5 ± 0.8 2.8 ± 0.8
nPCR, g/kg/day 1.13 ± 0.30 1.32 ± 0.34d 1.21 ± 0.34e 1.33 ± 0.28d
Kt/V* 1.45 ± 0.25 1.43 ± 0.26 1.40 ± 0.25 1.40 ± 0.23
Mean pre-HD blood pressure, mmHg 95 ± 15 100 ± 14 94 ± 16 97 ± 15
ACEI and/or ARB, % 28 28 28 21
Karnofsky score 72 ± 18 79 ± 16c 76 ± 18 80 ± 16c
Clinical comorbidity, %
Coronary artery disease 27 17 13 20
Congestive heart failure 2 5 2 3
Peripheral vascular disease 8 11 4 3
Stroke 14 12 12 7
Neoplasm 8 7 12 3
Chronic lung disease 2 0 1 1
Liver cirrhosis and/or hepatoma 5 1 4 3
No co-morbidity 47 64a 58 67a
Death rate, %(n) 40 (37) 28 (32) 28 (35) 23 (22)a
Laboratory data
hs-CRP, mg/L, median 16.32 7.69 8.24 3.78
(1st -3rd quartile ranges) (2.05-20.4) (0.70-8.73)g (0.88-7.33)g (0.93-4.85)h
Pre-albumin, mg/dL 29.1 ± 10.0 33.6 ± 9.3c 32.6 ± 9.4c,e 36.2 ± 8.9d
Albumin, g/dL 3.7 ± 0.5 4.0 ± 0.4d 3.9 ± 0.4e 4.1 ± 0.4d
Sodium, mmol/L 134.6 ± 2.9 135.4 ± 2.3f 139.6 ± 2.1d 139.3 ± 2.0d
Potassium, mmol/L 3.8 ± 0.5 5.3 ± 0.7d,e 3.8 ± 0.5f 5.0 ± 0.5d
Phosphate, mg/dL 4.2 ± 1.5 5.2 ± 1.7d 4.4 ± 1.4f 5.2 ± 1.4d
BUN, mg/dL 65 ± 23 85 ± 24d 67 ± 20f 80 ± 17d
Creatinine, mg/dL 8.5 ± 2.8 10.0 ± 2.5d 9.8 ± 2.5c 10.6 ± 2.5d
Uric acid, mg/dL 7.2 ± 1.5 8.2 ± 1.8d 7.5 ± 1.5e 8.1 ± 1.2d
Hematocrit, % 27.0 ± 5.3 28.2 ± 5.1 26.8 ± 4.3 27.9 ± 4.1
Abbreviations: HD hemodialysis, nPCR normalized protein catabolism rate, ACEI angiotensinogen converting enzyme inhibitor, ARB angiotensin receptor blockade,
hs-CRP high sensitivity C-reactive protein, BUN blood urea nitrogen. *: Gotch formula.
Statistics:
a: p < 0.05 vs. group 1 (χ2 tests).
c: p < 0.05, d: p < 0.001 vs. group 1 (ANOVA with post hoc Bonferroni tests).
e: p < 0.05, f: p < 0.001 vs. group 4 (ANOVA with post hoc Bonferroni tests).
g: p < 0.05, h: p < 0.001 vs. group 1(Kruskal–Wallis one-way analysis of variance).
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vs. 4.6 ± 1.4%, p = 0.001) and BUN-to-creatinine ratio
(8.50 ± 3.27 vs. 7.39 ± 2.08, p < 0.001) were found in the
lower S[Na] group (Groups 1 and 2) compared to the
high S[Na] group (Groups 3 and 4).Comparison of the long-term survival divided by serum
sodium and potassium concentrations
Lower S[Na] patients had a significantly poorer cumula-
tive survival than the higher S[Na] counterparts (p = 0.01)
(Figure 2A). The cumulative survival rate of the lower S
Table 2 Multivariate logistic regression analyses of the
clinical associations of Groups 1 and 4
95% CI
OR Lower Upper p
A. Group 1a
nPCR, g/kg/day 0.37 0.16 0.83 0.02*
Albumin, g/dL 0.37 0.20 0.67 <0.001*
B. Group 4b
nPCR, g/kg/day 2.26 1.05 4.86 0.04*
Albumin, g/dL 2.26 1.17 4.39 0.02*
a. dependent variable: Group 1 (n = 92) vs. others (Groups 2,3, and 4; n = 332).
b. dependent variable: Group 4 (n = 96) vs. others (Groups 1,2, and 3; n = 328).
Abbreviations: CI confidence interval, nPCR normalized protein catabolic rate,
HD hemodialysis.
*Adjusted for diabetes mellitus, gender, age at initiation of study, and
HD vintage.
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[K] counterparts (p = 0.15) (Figure 2B). In the combined
analysis of the two electrolytes, Group 1 had a poorer
outcome compared to Groups 3 and 4, but there was no
statistical difference among Groups 2, 3, and 4 (Figure 2C).
After adjustment for DM, gender, HD duration, and age
at the beginning of study, as compared to the reference
(Group 1), the hazard ratio for mortality was significantly
lower in Groups 3 (HR = 0.54, 95% CI = 0.34-0.86) and 4
(HR = 0.49, 95% CI = 0.28-0.84) (Figure 3).
Characteristics of patients with Groups 1 and 4
As shown in Figure 2, those patients with both lower S
[Na] and S[K] (Group 1) had the worst long-term prog-
nosis while those patients in Group 4, with both higher
S[Na] and S[k], had the better outcomes. Therefore, we
attempted to characterize the clinical association of these
two groups. After adjustment for DM, gender difference,
age at initiation of study, and HD vintage in multivariate
logistic regression tests, Group 1 was associated with
lower nPCR (OR: 0.37; 95% CI = 0.16-0.83) and hypoal-
buminemia (OR: 0.37; 95% CI = 0.20-0.67). Conversely,Table 3 Cox proportional method for evaluation the risk fact
Univariate
HR 95% CI
Group 1 (vs. other 3 groups)* 1.78 1.21 2.61
Sodium, mmol/dL 0.92 0.88 0.97
Potassium, mmol/dL 0.80 0.65 0.98
Diabetes (vs. non-diabetes) 1.64 1.15 2.34
Male (vs. female) 1.06 0.75 1.51
Age※, year 1.05 1.04 1.07
HD duration, month 1.00 1.00 1.01
Abbreviations: CI confidence interval, HD hemodialysis, *: group 1 vs. the other 3 group
#: adjusted for diabetes mellitus, gender, age, and HD vintage.Group 4 was associated with higher levels of nPCR
(OR: 2.26; 95% CI = 1.05-4.86) and albumin (OR: 2.26;
95% CI = 1.17-4.39).
Long-term serum sodium, potassium and albumin
concentration changes
Figure 1 shows the serial changes of S[Na] and S[K]
throughout the study period. Those patients with either
lower S[Na] or S[K] at baseline had persistently lower
levels of S[Na] and S[K] (Figure 1B & D). Both also
had consistently lower serum albumin concentrations
(Figure 1A & B).
Cox proportional method for evaluation the risk factors
related to mortality
As can be seen in Table 3, Group 1, lower S[Na], lower S
[K], DM, and old age were risk for death in univariate Cox
proportional analysis. After adjusting for DM, gender, age
at the initiation of study, and HD vintage by multivariate
study, Group 1 was found to be an independent factor for
long-term mortality (HR: 1.74; 95% CI: 1.18-2.58).
Discussion
This is the first report to address the combination effect
of S[Na] and S[K] on the long-term survival of chronic HD
patients. The main finding was that patients with lower S
[K] superimposed with lower S[Na] were characterized
by hypoalbuminemia and lower nPCR level. They were
also associated with higher hs-CRP level, and more co-
morbidity. The combination of lower levels of both elec-
trolytes in HD patients was proven to be an independent
factor leading to a high long-term mortality. In contrast,
HD patients with higher levels of both electrolytes tended
to have better outcomes.
Recently, lower pre-HD S[Na] has been reportedly
associated with an increased risk of all-cause mortality
in HD patients [9,17], but the mechanism for this remains
obscure. We suggest several hypotheses. A high catabolic
rate and inflammation status may be a cause, since weors related to long-term mortality
Multivariate
p HR 95% CI p
0.003 1.74 1.18 2.58 0.006#
0.002
0.03
0.006 1.71 1.17 2.49 0.005
0.74 1.35 0.95 1.93 0.10
<0.001 1.05 1.04 1.07 <0.001
0.26 1.00 0.99 1.01 0.10
s, death rate: 37/92 (40%) vs. 89/332 (27%),※: Age at the initiation of study.
Figure 2 (See legend on next page.)
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Figure 2 Comparison of the long-term survival divided by serum sodium and potassium concentrations. The patients with low serum
sodium concentration (S[Na], Groups 1, and 2) had a poorer cumulative survival than their counterparts (p = 0.010, 2A). Cumulative survival rate of
lower serum potassium (S[K]) group was non-significantly lower than that of the higher S[K] group (p = 0.147, 2B). After investigating the combination
of the two electrolytes, Group 1 was found to have a poorer outcome compared to Groups 3 and 4. There was no difference among Groups 2, 3,
and 4 (2C).
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hs-CRP and BUN-to-creatinine ratio (BUN/Cr) in this
study. A high ratio of BUN/Cr has been recognized as a
marker of high catabolism rate in clinical practice.
Hypervolemia may be another factor. The patients with
lower S[Na] had a significantly higher level of ultrafiltra-
tion rate. This may have been caused by either previous
inadequate ultrafiltration and/or over-ingestion of fluid
during the inter-dialysis period, eventually leading to
chronic fluid retention. Higher interdialytic weight gain
was also correlated with poor survival and increased
cardiovascular death [18], with patients of lower S[Na]
as compared to their higher S[Na] counterparts also
having a higher percentage of DM. Diabetes patients with
impaired autonomic nervous system tended to develop
intra-dialysis hypotension [19], resulting in an inadequate
ultrafiltration rate and a failure to achieve a real dry
weight. Both these factors lead to chronic fluid retention
and lowering of the S[Na]. Hyperglycemia, dipsogenic fac-
tors, and poor compliance to salt restriction with re-
sultant high fluid intake might also be contributory
factors to lower S[Na] [20]. Eventually, all of these factors
were associated with hypervolemia, thus resulting in
congestive heart failure and mortality risk. Hypervolemia
is an important factor contribution to the long-term
mortality of HD patients [21].
HyperK in HD patients was demonstrated to have a
high risk of mortality by Kovesdy. However, we found
that the patients with lower S[K] were associated withFigure 3 Hazard ratios for mortality among each group after
adjusted risk factors. After adjustment for DM, gender, HD duration,
and age at the beginning of study, the hazard ratio for mortality was
significantly lower in Group 3 (HR = 0.54, 95% CI = 0.34-0.86), followed
by Group 4 (HR = 0.49, 95% CI = 0.28-0.84).non-significantly worse long-term outcomes. HypoK
patients with S[K] less than 3.5 mmol/L were reported
to have a higher mortality risk than patients with higher
S[K] [12]. This observational discrepancy may result from
different patient characteristics. Our patients, for example,
tended to suffer more frequently from malnutrition than
metabolic syndrome. BMI values of our patients were
significantly lower (21–22 vs. 26) [12]. Some of their
patients were dialyzed with more than 2–3 mmol/L in
dialysate K bath [12]. CKD patients not on dialysis with
low or even low-normal S[K] were observed to be at a
higher risk of dying than those with mild to moderate
hyperkalemia. In our study, lower S[K] patients were
associated not only with lower levels of nPCR and albumin,
but also with a high level of hs-CRP. These features signify
that these patients are characterized with more severe
malnutrition and higher inflammation status. We hypo-
thesize that HD patients with lower S[K] may also be
under a catabolic rate and protein-energy wasting status
[22]. They also had a higher prevalence of co-morbid
conditions, thus further associating lower S[K] with
high mortality.
Group 1 was associated with lower levels of serum
albumin and nPCR. This could explain why “Group 1” lost
statistical significance in predicting long-term outcome in
model 2 Cox proportional analyses after the addition of
“albumin” as a covariate. In clinical practice, HD patients
having low levels of both serum albumin and nPCR are
invariably indicative of the worst clinical conditions [23].
Both hypoalbuminemia and low nPCR are also indicated
as good surrogate markers for all-cause mortality in HD
patients. This could explain why the patients in Group 1
were associated with worse long-term prognoses.
From our data, lower S[Na] is definitely much worse
than higher S[Na], and lower S[K] is tends to be a little
worse than higher S[K]. When combining the two, the
long-term effects of lower S[K] are a cause for concern,
but they may be overlooked. While extreme hyperkalemia
may always be serious, when cutting in the middle,
patients are better off being on the relatively higher S
[K] side rather than the lower S[K] side.
In this study, we found consistency of S[Na] and S[K]
in the chronic HD patients over the course of 54 months.
This invariable phenomenon has been reported before
[12,24]. Hypoalbuminemia was persistently noted in the
patients characterized by either lower S[Na] or lower S
[K] throughout the whole study period. This stability in
Hwang et al. BMC Nephrology 2013, 14:269 Page 8 of 9
http://www.biomedcentral.com/1471-2369/14/269low serum albumin concentrations suggests that those
patients with a lower level of either electrolyte share some
intrinsic factors, which cause long-standing malnutrition
and sub-clinical inflammation. This could explain the high
mortality rate in these patients.
Contrary to Group 1, Group 4 had the lower prevalence
of diabetes and level of hs-CRP, as well as higher levels
of serum pre-albumin, albumin, creatinine, and nPCR.
This means that these patients are under relatively better
nutrition and suffer rather less inflammation. Group 4
patients also had a higher Karnofsky score than Group
1. These features could explain the better survival in
these patients compared to the other groups.
As far as we know, no data has yet been reported on
the impact of the combined effect of S[K] and S[Na] on
the long-term prognosis in chronic HD patients. One
strength of our study is the 4.5-year length of follow-up.
But there are also some limitations to this study. First,
we did not check body volume directly, since we suspected
that lower S[Na] was the result of hypervolemia. Second,
the analysis was based on single sodium and potassium
values. Moreover, the dialysate composition was changed
shortly after baseline, which also may have influenced
the results. However, these omissions are not expected
to distort the deleterious impact of lower S[K] superim-
posed with lower S[Na] on the long-term prognosis of
HD patients.
Conclusions
In conclusion, our data demonstrated that HD patients
with lower levels of both S[K] and S[Na] were associated
with poor cumulative survival. They were associated with
hypoalbuminemia, and lower nPCR levels. Independent
of the traditional risk factors including DM, age, gender
and HD vintage, both electrolytes under lower levels
are able to predict the worst long-term outcomes for
HD patients. On the other hand, those patients with
higher levels of both S[Na] and S[K] were found to
have better long-term prognoses. Although we suspect
that persistent malnutrition, high inflammation status,
more co-morbidity risks, and chronic hypervolemia in
patients with lower S[Na] and S[K] were the main causes
leading to higher mortality, the real mechanism still needs
further clarification.
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